Botulinum Toxins Market Size & Growth Forecast to 2030
The global botulinum toxins market is projected to reach USD 15.72 billion by 2030, growing at a CAGR of 12.0% from USD 8.92 billion in 2025, driven by increasing aesthetic consciousness and expanding therapeutic applications. Key players include AbbVie, Ipsen, and Galderma, with significant market share in North America, while the Asia Pacific region is expected to show the highest growth. The market is influenced by a shift towards minimally invasive procedures, biosimilar competition, and product innovation.
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus, Inc. announced its plan to report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results, followed by a question-and-answer session. Details for participating in the call and accessing replays are provided.
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus, Inc. announced it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. The company's management will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results. Evolus is a performance beauty company focused on aesthetic injectables, including its flagship products Jeuveau® and Evolysse™.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 13, 2026
Evolus, Inc. reported inducement grants to 36 newly hired non-executive employees in December 2025, January 2026, and February 2026. The grants included 153,218 restricted stock units and 34,952 stock options, approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan as material inducements for joining the company. The awards vest 25% annually and are subject to continuous employment.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. announced the grant of 153,218 restricted stock units (RSUs) and 34,952 stock options to 36 new non-executive employees. These inducement grants were issued under the company's 2023 Inducement Incentive Plan, as material inducements for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards vest 25% annually and are subject to continuous employment.
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating
Mizuho analyst Uy Ear has lowered the price target for Evolus, Inc. (EOLS) to $15 from $19, while maintaining an Outperform rating. This adjustment follows a softer-than-anticipated preannounced fourth quarter, but reflects continued confidence in the company's long-term growth. Evolus, which focuses on injectable aesthetic treatments, reported $69 million in revenue in Q3 2025, driven by demand for Jeuveau and the launch of Evolysse.
Evolus, Inc. (NASDAQ:EOLS) Given Average Rating of "Moderate Buy" by Brokerages
Evolus, Inc. (NASDAQ:EOLS) has received an average "Moderate Buy" rating from seven brokerages, with an average one-year target price of $17.50, despite several firms recently lowering their price targets. Insider David Moatazedi sold a notable number of shares, though institutional investors collectively own a significant majority of the company's stock. The company's shares opened at $4.59, with recent revenue below expectations and negative earnings.
Mizuho lowers Evolus stock price target to $15 on guidance reset
Mizuho has adjusted its price target for Evolus (NASDAQ:EOLS) stock to $15 from $19, while maintaining an Outperform rating. This revision follows Evolus's lower-than-expected Q4 2025 results and revised 2026 revenue guidance, yet Mizuho remains positive due to the stock's "compelling" valuation. Other firms like H.C. Wainwright, BTIG, and Stifel also adjusted their targets but maintained Buy ratings.
HC Wainwright Lowers Evolus (NASDAQ:EOLS) Price Target to $13.00
HC Wainwright has reduced its price target for Evolus (NASDAQ:EOLS) to $13.00 from $20.00, while maintaining a "buy" rating, indicating a potential upside of 164.77%. The company's stock currently trades at $4.91, significantly below the analyst consensus target of $18.17. Despite a recent insider share sale and a revenue miss, Evolus beat EPS expectations in its last quarterly report, and institutional ownership remains high at approximately 90.69%.
Botulinum Toxin Market to Grow Strongly Through 2030 | Aesthetic
The botulinum toxin market is projected for strong growth through 2030, driven by increasing demand in both aesthetic and therapeutic applications. North America currently leads the market with a 40% share. Key players like Allergan, AbbVie, Ipsen, Merz Pharma, Revance Therapeutics, and Evolus are shaping the competitive landscape through innovation and expanded clinical indications across various regions.
BTIG lowers Evolus stock price target to $13 on aesthetic market decline
BTIG has lowered its price target for Evolus (NASDAQ:EOLS) to $13.00 from $18.00, while maintaining a Buy rating, following the company's updated 2026 and long-term guidance and a significant decline in the aesthetic injectables market. The stock has fallen 45% in six months, and despite management's assurances of market stabilization and commitment to profitability, analysts do not expect profitability in 2025. Other firms like Stifel and Mizuho have also reduced their price targets, though H.C. Wainwright reiterated a Buy rating.
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research
BTIG Research has lowered its price target for Evolus (NASDAQ:EOLS) to $13.00 from $18.00, while maintaining a "buy" rating, indicating a potential upside of 165.31% from its current share price. The company received an average "Moderate Buy" rating from analysts with an average target of $19.33, despite trading around $4.90 and reporting a revenue miss in its last quarter. Insider selling and institutional investment details were also highlighted.
Understanding Momentum Shifts in (EOLS)
This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate three distinct trading strategies: A Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. It provides an overview of the signals generated for EOLS, including multi-timeframe signal analysis, and offers access to real-time institutional-grade analysis for subscribers.
BTIG lowers Evolus stock price target to $13 on aesthetic market decline
BTIG has lowered its price target for Evolus (NASDAQ:EOLS) to $13.00 from $18.00, while maintaining a Buy rating, due to a decline in the aesthetic injectables market and updated guidance from the company. Despite concerns about market recovery and competition, Evolus reported strong preliminary Q4 2025 revenues and reaffirmed positive non-GAAP operating income. Other analysts, including Stifel and Mizuho, have also adjusted their price targets, reflecting a mixed outlook for the company.
Evolus projects robust 2025 growth with upcoming product launches
Evolus (EOLS) is anticipating significant growth in 2025, driven by the planned launches of its new neuromodulator, Evolysse, and its biosimilar to Johnson & Johnson's Stelara. Despite a strong performance in 2024, the company expects these new products to substantially boost its market position and revenue in the coming year, particularly from its Esthetics segment.
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop
Evolus, Inc. (NASDAQ:EOLS) has seen a significant 30% drop in its stock price this month, contributing to a 50% loss over the past year. Despite a low price-to-sales (P/S) ratio of 1.1x compared to the industry average, the market anticipates continued poor revenue growth. Analysts forecast only 19% annual revenue growth for Evolus over the next three years, significantly lower than the industry's projected 32% growth, which explains the suppressed P/S ratio.
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00
Stifel analyst Annabel Samimy has lowered the price target for Evolus (EOLS) to $17.00 from $20.00, while maintaining a "Buy" rating. This adjustment reflects a 15.00% decrease in the price target. Despite the lowered target, the average target price from 6 analysts is $18.00, implying a significant upside from the current price, and the average brokerage recommendation is "Outperform."
Stifel lowers Evolus stock price target to $17 on tempered growth outlook
Stifel has lowered its price target for Evolus (NASDAQ:EOLS) to $17 from $20, while maintaining a Buy rating, following the company's preliminary 2025 revenues and "tepid" 2026 guidance. The revision reflects a significant reduction in Evolus's long-term revenue outlook for 2028, attributed to a weak macro environment. Despite the tempered growth, Evolus aims for full-year profitability in 2026 through cost optimization, and analysts generally maintain a "Strong Buy" consensus, with some also lowering price targets but reaffirming positive ratings.
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00
Stifel analyst Annabel Samimy has lowered the price target for Evolus (EOLS) from $20.00 to $17.00, while maintaining a "Buy" rating. This adjustment reflects a 15% decrease in the price target. Despite the reduction, the average analyst target for EOLS is $18.00, implying a significant upside from its current price, with GuruFocus estimating a fair value of $16.90.
Stifel lowers Evolus stock price target to $17 on tempered growth outlook
Stifel has lowered its price target for Evolus (NASDAQ:EOLS) to $17, down from $20, while maintaining a Buy rating. This adjustment follows Evolus's preliminary 2025 net revenues coming in at the low end of expectations and a significant reduction in its long-term outlook, with 2028 revenue guidance cut by 30-35%. Despite this "dramatic reset to expectations," Evolus maintained 15.1% revenue growth over the past year, and the company still anticipates full-year profitability in 2026.
Avoiding Lag: Real-Time Signals in (EOLS) Movement
This article analyzes Evolus Inc. (NASDAQ: EOLS), highlighting weak market sentiment across all time horizons and supporting a short bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis with support and resistance levels for near-term, mid-term, and long-term periods.
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts
Evolus, Inc. (NASDAQ:EOLS) has received a "Moderate Buy" consensus rating from six analysts, with an average one-year price target of $20.80. The company's stock is trading near its 12-month low despite beating EPS estimates in its last quarter, though revenue missed consensus. Insider David Moatazedi recently sold shares, while institutional investors hold a significant portion of the stock.
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Evolus, Inc. announced preliminary unaudited net revenues for Q4 and full-year 2025, showing double-digit growth. The company expects Q4 2025 net revenue between $88.6 million and $90.6 million, and full-year 2025 net revenue between $295.5 million and $297.5 million. Evolus also provided 2026 net revenue guidance of $327.0 million to $337.0 million, anticipates sustainable annual profitability starting in 2026, and updated its 2028 long-term financial outlook to reflect total net revenue of $450 million to $500 million.
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com
Evolus, Inc. announced preliminary unaudited fourth quarter 2025 revenue between $88.6 million and $90.6 million, marking a 12% to 15% growth year-over-year. The aesthetic medicine company projects revenue between $327 million and $337 million for 2026 and expects to achieve sustainable annual profitability starting that year, despite analyst predictions that it won't be profitable this year. Evolus also updated its long-term financial outlook, aiming for 2028 revenue between $450 million and $500 million, with non-GAAP operating income margins of 13% to 15%.
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M
Evolus (EOLS) announced preliminary Q4 2025 revenue between $88.6 million and $90.6 million, falling slightly short of the $90.91 million consensus. CEO David Moatazedi highlighted strong performance, including double-digit growth for the sixth consecutive year, diversification with a second product line, accelerated international expansion, and achieving profitability in Q4 2025. This performance underscores the company's "performance beauty strategy" and market share gains in a challenging environment.
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M
Evolus provided its fiscal year 2026 revenue outlook, projecting between $327 million and $337 million, which falls below the consensus estimate of $351.66 million. The company aims for a measured return to market growth through increased U.S. penetration and international expansion, expecting improved profitability through disciplined spending. Evolus has recalibrated its long-term financial targets to reflect growing market share against a more conservative market growth outlook, asserting confidence in achieving above-market growth and profitability.
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market
Evolus, Inc. (EOLS) is presented as an intriguing investment opportunity in the cash-pay aesthetic market, with a current stock price of $5.74 and a market capitalization of $372.07 million. Despite current unprofitability and negative free cash flow, analysts are highly optimistic, with an average price target of $18.50, suggesting a potential upside of 222.30%. The company specializes in products like Jeuveau and Evolysse, demonstrating strong revenue growth but also the typical cash burn of a growth-oriented healthcare firm.
Evolus outlook FY sales USD 327-337 million
Evolus, Inc. projects its full-year sales to be between USD 327-337 million. This outlook follows the company's reaffirmation of preliminary unaudited earnings guidance for the fourth quarter of 2025 and 2026, and newly provided guidance for 2028. Evolus specializes in performance beauty products, including neurotoxins like Jeuveau and hyaluronic acid dermal fillers under the Evolysse line.
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Evolus, Inc. announced preliminary unaudited net revenues for Q4 and full-year 2025, showing double-digit growth. The company expects Q4 2025 net revenue between $88.6 million and $90.6 million, and full-year 2025 net revenue between $295.5 million and $297.5 million. Evolus also provided 2026 net revenue guidance of $327 million to $337 million and reaffirmed its projection for sustainable annual profitability beginning in 2026.
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value
Insiders at Evolus, Inc. sold US$1.5 million worth of stock over the past year at an average price of US$10.30, which is still above the current share price of US$5.91 despite a recent 11% stock drop. The largest sale was by President David Moatazedi for US$1.3 million at US$10.05 per share. While insider selling occurred at a higher price than the current market value, company insiders still maintain a 9.9% ownership, valued at US$39 million.
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value
Evolus, Inc. insiders sold US$1.5m worth of stock over the past year at an average price of US$10.30, which is higher than the current share price of US$5.91. Despite a recent 11% stock price drop, these sales suggest insiders might have been better off holding. While there were no insider transactions in the last three months, insiders still own 9.9% of the company, valued at US$39m.
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS)
Analysts have provided insights into Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS), two companies in the Healthcare sector. William Pickering from Bernstein maintained a Hold rating on Arrowhead Pharmaceuticals with a $35.00 price target, while Sam Eiber from BTIG maintained a Buy rating on Evolus with an $18.00 price target. The Street consensus suggests a Moderate Buy for Arrowhead and a Strong Buy for Evolus.
Discipline and Rules-Based Execution in EOLS Response
This article provides a detailed analysis of Evolus Inc. (NASDAQ: EOLS), highlighting specific trading strategies and risk parameters generated by AI models. It identifies a near-term weak sentiment that may lead to a resumption of long-term weakness and outlines a high risk-reward short setup. The analysis includes position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for EOLS.
Avelar Rui, Evolus officer, sells $16k in EOLS stock
Evolus Chief Medical Officer Rui Avelar sold 2,261 shares of EOLS stock worth $16,167 on December 22, 2025, to cover tax obligations. Despite a year-to-date decline of 37.5% and unprofitability, analysts maintain a cautiously optimistic outlook on Evolus, with price targets ranging from $14 to $20, citing strong revenue growth.
Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock
Rui Avelar, an insider at Evolus, Inc. (NASDAQ:EOLS), sold 2,261 shares of the company's stock on December 22nd at an average price of $7.15, reducing his stake by 0.63%. This transaction follows a quarterly earnings report where Evolus beat EPS estimates but missed revenue forecasts, remaining unprofitable. Analysts hold a "Moderate Buy" consensus rating with an average target price of $20.80, while institutional investors maintain a significant ownership of 90.69% in the company.
Evolus CEO Moatazedi sells $75k in shares
Evolus CEO David Moatazedi sold 10,539 shares of company stock for approximately $75,361 on December 22, 2025, to cover tax obligations. Despite this, analysts like Mizuho and H.C. Wainwright maintain positive ratings, with Mizuho noting a potential easing of a longstanding stock overhang related to an intellectual property settlement with Medytox. These developments provide insights into Evolus's market position and future trajectory amidst macroeconomic challenges.
Evolus CEO Moatazedi sells $75k in shares By Investing.com
Evolus CEO David Moatazedi sold 10,539 shares of the company's common stock for approximately $75,361 on December 22, 2025, to cover tax withholding obligations. This transaction leaves him with 354,388 directly owned shares. Meanwhile, analysts like Mizuho and H.C. Wainwright have maintained positive ratings on Evolus, despite some adjustments to price targets due to market sentiments and past intellectual property settlements.
Evolus CEO Moatazedi sells $75k in shares By Investing.com
Evolus CEO David Moatazedi sold 10,539 shares for approximately $75,361 on December 22, 2025, to cover tax obligations. Following this, Moatazedi directly owns 354,388 shares of Evolus, Inc. Analysts at Mizuho and H.C. Wainwright have reiterated Outperform and Buy ratings, respectively, on EOLS, with price targets ranging from $19.00 to $20.00, despite some adjustments due to market sentiment and a lingering stock overhang.
Avelar Rui, Evolus officer, sells $16k in EOLS stock
Evolus Chief Medical Officer Rui Avelar sold 2,261 shares of EOLS stock worth $16,167 on December 22, 2025, to cover tax obligations. Despite a 37.5% year-to-date decline in shares, analysts offer a mixed but cautiously optimistic outlook on Evolus, with Mizuho lowering its price target due to consumer sentiment while H.C. Wainwright reiterated a Buy rating. The company's future performance is being monitored by analysts, with early signs of market stabilization noted in the neurotoxin market.
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 10,539 Shares of Stock
Evolus (NASDAQ:EOLS) insider David Moatazedi sold 10,539 shares of the company's stock on December 22nd, reducing his stake by 2.89%. The sale, valued at $75,353.85, leaves him with 354,388 shares. Despite the sell-off, institutional investors hold a significant portion of Evolus stock, and analysts maintain a "Moderate Buy" consensus with an average target price of $20.80.
Needham Reiterates Evolus (EOLS) Hold Recommendation
Needham has reiterated a "Hold" recommendation for Evolus (EOLS). The average one-year price target for Evolus is $18.87/share, suggesting a 177.09% upside from its latest closing price of $6.81/share. Institutional ownership data shows varying activities among major holders like Nantahala Capital Management and Tang Capital Management.
Evolus' (EOLS) "Hold" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC has reaffirmed its "Hold" rating on Evolus (NASDAQ:EOLS), despite mixed analyst coverage that results in an average consensus of "Moderate Buy" with a $20.80 price target. The company's shares opened lower, trading at $6.81, significantly below its 1-year high. Evolus recently reported a narrower-than-expected loss but missed revenue estimates, and continues to show negative net margin and return on equity.
Needham Reiterates Hold Rating for Evolus (EOLS) | EOLS Stock News
Needham has reiterated a Hold rating for Evolus (EOLS) with no change to its price target, according to an update on December 24, 2025. This comes amidst varied analyst ratings and price target adjustments for Evolus in recent months, reflecting diverse perspectives on the company's market trajectory. Despite the varied ratings, the average target price from Wall Street analysts suggests a significant upside from the current stock price.
Trading the Move, Not the Narrative: (EOLS) Edition
This article presents an AI-driven analysis for Evolus Inc. (NASDAQ: EOLS), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis for near, mid, and long-term horizons.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflati***onary Pressure on Elective Aesthetics
Mizuho has lowered its estimates for Evolus's Jeuveau and Evolysse products and reduced its price target to $19 from $20 due to waning consumer sentiment and inflationary pressures affecting elective aesthetic procedures. Despite these challenges, Evolus reported strong Q3 2025 results with global net revenue up 13% year-over-year, driven by Jeuveau, and maintained a positive long-term outlook. The company's customer loyalty program and expanding professional customer base indicate a strong market position even as the overall aesthetic market faces spending challenges.
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Evolus, Inc. (NASDAQ:EOLS) has received a consensus "Moderate Buy" rating from brokerages, with an average one-year target price of $20.80. The company reported mixed quarterly results, beating EPS estimates but missing revenue expectations, and continues to operate at a loss. Institutional investors hold a significant portion of the stock, with some increasing their positions recently.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Mizuho has lowered its price target for Evolus (EOLS) to $19 from $20, while maintaining an Outperform rating. This adjustment reflects a downward revision of estimates for its products, Jeuveau and Evolysse, due to declining consumer sentiment and anticipated inflationary pressures affecting demand for elective facial aesthetic procedures. Despite this, Evolus reported strong Q3 2025 revenues ($69 million, up 13% year-over-year) driven by Jeuveau, and maintains a positive full-year 2025 revenue outlook of $295-$305 million.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Mizuho has lowered its price target for Evolus (EOLS) to $19 from $20, while maintaining an Outperform rating, due to waning consumer sentiment and inflationary pressures affecting demand for elective aesthetic procedures. Despite these headwinds, Evolus reported strong Q3 2025 revenues of $69 million and increased its 2025 outlook, driven by its flagship neurotoxin Jeuveau and early contributions from Evolysse. The company continues to face challenges in the US aesthetic market, particularly in the HA filler segment, but expects long-term growth.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Mizuho has lowered its price target for Evolus (EOLS) to $19 from $20, while maintaining an Outperform rating. This revision is due to waning consumer sentiment and inflationary pressures impacting demand for elective aesthetic procedures, despite Evolus's strong Q3 2025 performance and market share growth. The company's products, Jeuveau and Evolysse, face headwinds from a challenging US aesthetic market and a double-digit decline in the HA filler market.
2,435,550 Shares in Evolus, Inc. $EOLS Bought by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. acquired a new stake of 2,435,550 shares in Evolus, Inc. (NASDAQ:EOLS) during the second quarter, valued at approximately $22.43 million. This purchase makes Evolus the 24th largest position in Frazier Life Sciences' portfolio, representing about 3.77% ownership. The article details other institutional investments in Evolus, along with recent analyst ratings and the company's financial performance.
